Hematologic Malignancy
Acute Myeloid Leukemia
CI-CAN-00001674AML · ANLLExplore in graph →
Hematologic789 active trials18 approved drugs279 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001674AML · ANLLExplore in graph →
Clinical trials
2,962 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (534)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07841002 | CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia | not yet recruiting | Phase 1 | 12 | Liping DouOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07828535 | Liposomal Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit AML | not yet recruiting | Phase 1 | 30 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Sep 18, 2026 | clinicaltrials |
| NCT07826897 | Real-Time Breath Analysis in Acute Myeloid Leukaemia for a Rapid Characterisation of Biological Subtypes and to Predict Therapy Responses(EXHALE) | not yet recruiting | — | 120 | Jeremy DeuelOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07819396 | Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome | not yet recruiting | Phase 2 | 52 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07676006 | A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia | not yet recruiting | Early Phase 1 | 36 | Grit BiotechnologyINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07605949 | Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML(RAVEN) | not yet recruiting | Phase 2 | 88 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07623187 | A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy(EVICTION 3) | not yet recruiting | Phase 2 / Phase 3 | 540 | IpsenINDUSTRY | 0 | Sep 10, 2026 | clinicaltrials |
| NCT07710781 | Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies | not yet recruiting | N/A | 300 | Ossium Health, Inc.INDUSTRY | 0 | Sep 10, 2026 | clinicaltrials |
| NCT07814339 | Hydrochloroquinine & Decitabine With Venetoclax in AML | not yet recruiting | Phase 1 | 18 | Rutgers, The State University of New JerseyOTHER | 0 | Sep 10, 2026 | clinicaltrials |
| NCT06954987 | Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | not yet recruiting | Phase 2 | 244 | National Cancer Institute (NCI)NIH | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07153497 | Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy) | not yet recruiting | Phase 2 | 132 | National Cancer Institute (NCI)NIH | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07809984 | Prevention of Oral Mucositis in Adults in With Hematologic Malignancy | not yet recruiting | N/A | 206 | Wake Forest University Health SciencesOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07810829 | Prognostic Value of CAR, AFR and Ferritin in Non-M3 AML | not yet recruiting | — | 208 | Assiut UniversityOTHER | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07802015 | Home-based Intravenous Cytarabine Treatment for Acute Myeloid Leukemia: a National Danish Study of Feasibility, Costs, and Implementation(HOME-CALM) | not yet recruiting | — | 80 | Zealand University HospitalOTHER | 0 | Sep 3, 2026 | clinicaltrials |
| NCT05995041 | Universal CAR-T Cells Targeting AML | not yet recruiting | Phase 1 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT03222674 | Multi-CAR T Cell Therapy for Acute Myeloid Leukemia | not yet recruiting | Phase 1 / Phase 2 | 10 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04033302 | Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies | not yet recruiting | Phase 1 / Phase 2 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05995028 | Universal 4SCAR7U Targeting CD7-positive Malignancies | not yet recruiting | Phase 1 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT07754799 | A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia | not yet recruiting | Phase 2 | 320 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Aug 26, 2026 | clinicaltrials |
| NCT07053020 | A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML) | not yet recruiting | Phase 1 / Phase 2 | 58 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07777471 | Improving Delivery of Aging-Related Supportive Care for Older Adults With Acute Myeloid Leukemia(ACTIVE DEFAULT) | not yet recruiting | N/A | 40 | University of Alabama at BirminghamOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07780565 | Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome | not yet recruiting | Phase 1 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT07549464 | Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia | not yet recruiting | Phase 1 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07770698 | A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia | not yet recruiting | Phase 1 / Phase 2 | 30 | BeOne MedicinesINDUSTRY | 0 | Aug 18, 2026 | clinicaltrials |
| NCT07761702 | Umbilical Cord Blood Consolidation for Older Adults With Intermediate- and High-Risk AML | not yet recruiting | Phase 3 | 132 | Shanghai Jiao Tong University School of MedicineOTHER | 0 | Aug 12, 2026 | clinicaltrials |
| NCT07758218 | Allogeneic iNKT Cell Therapy (agenT-797) After SCT | not yet recruiting | Phase 1 | 22 | University of Wisconsin, MadisonOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07755202 | Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia(GAVE001) | not yet recruiting | Phase 2 | 20 | Florian KuchenbauerOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07751588 | Plasma ctDNA Monitoring in Pediatric Acute Leukemia | not yet recruiting | — | 25 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07570056 | Use of Electrical Bioimpedance in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients (Bioimpedance) | not yet recruiting | — | 25 | University of UtahOTHER | 0 | Aug 6, 2026 | clinicaltrials |
| NCT07743047 | Harnessing the Immunosuppressive Leukemic Microenvironment to Engineer T Cells With Enhanced Anti-tumor Functionality(SynT) | not yet recruiting | — | 65 | IRCCS San RaffaeleOTHER | 0 | Aug 6, 2026 | clinicaltrials |
| NCT07749976 | GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 108 | VitruviaeINDUSTRY | 0 | Aug 6, 2026 | clinicaltrials |
| NCT07748455 | HMA-Venetoclax Induction in Newly Diagnosed AML(VENTURE-AML) | not yet recruiting | Phase 2 | 60 | Pakistan Blood and Marrow Transplant (PBMT) GroupOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07737769 | Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome | not yet recruiting | Phase 1 | 20 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07735117 | Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML | not yet recruiting | Phase 3 | 168 | Ruijin HospitalOTHER | 0 | Jul 29, 2026 | clinicaltrials |
| NCT07735208 | Geriatric Assessment-Guided Treatment Selection in Older Adults With Acute Myeloid Leukemia(ALIGN-AML) | not yet recruiting | Phase 2 | 120 | University of RochesterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07717164 | PRAISE-IR Versus CIBMTR Controls | not yet recruiting | — | 51 | Miltenyi Biomedicine GmbHINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07722767 | A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients | not yet recruiting | Phase 1 | 90 | Cullinan Therapeutics Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07719348 | A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies | not yet recruiting | Phase 1 / Phase 2 | 64 | ServierINDUSTRY | 0 | Jul 22, 2026 | clinicaltrials |
| NCT07254793 | Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT | not yet recruiting | Phase 1 | 94 | University of ArizonaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07696481 | Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia(R/R AL) | not yet recruiting | Early Phase 1 | 18 | Zhujiang HospitalOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07686965 | Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at High Risk of Relapse | not yet recruiting | Phase 3 | 191 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jul 7, 2026 | clinicaltrials |
| NCT07597941 | Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients | not yet recruiting | Phase 2 / Phase 3 | 20 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 0 | Jun 30, 2026 | clinicaltrials |
| NCT07528417 | Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX)(MYELO-CAN:ABX) | not yet recruiting | Phase 2 | 75 | University of ManitobaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07664839 | Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations | not yet recruiting | Phase 2 | 148 | Shen yangOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07572929 | A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant(PREeMPT) | not yet recruiting | Phase 2 | 450 | Medical College of WisconsinOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07563010 | Menin-Inhibitor Targeted Maintenance in AML | not yet recruiting | Phase 2 | 146 | Center for International Blood and Marrow Transplant ResearchNETWORK | 0 | Jun 22, 2026 | clinicaltrials |
| NCT07643636 | Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AML | not yet recruiting | Phase 2 | 46 | Dongguan People's HospitalOTHER_GOV | 0 | Jun 18, 2026 | clinicaltrials |
| NCT07644481 | Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission | not yet recruiting | N/A | 30 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jun 12, 2026 | clinicaltrials |
| NCT07642453 | VA-CAG Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed Acute Myeloid Leukemia. | not yet recruiting | Phase 2 | 110 | Hematology department of the 920th hospitalOTHER | 0 | Jun 11, 2026 | clinicaltrials |
| NCT07575412 | SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS | not yet recruiting | Phase 2 | 180 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 25, 2026source: clinicaltrials